A newly constructed antibody‒drug conjugate targeting CD19 incorporating triptolide, a bioactive component from traditional SLE treatment Tripterygium wilfordii Hook F, exhibited excellent therapeutic CD19+ B‐cell depletion efficacy in MRL/lpr mice in vivo and in human PBMCs in vitro [175]. This evidence concerns the gene CD19 and systemic lupus erythematosus.